Table 1. Synergistic killing of tumor cells with panbinostat and LMB-100.

Cell Lines	Tumor types	Control	Panb	LMB-100	Panb +LMB-100	Synergy score (Cl)
KLM-1	Pancreatic	6.5±1.3	28.2±6.0	36.8±0.6	79.9±3.5	0.62
BxPC3	Pancreatic	9.8±2.1	19.3±2.2	13.5±0.2	35.4±2.9	0.50
HAY	Mesothelioma	5.5±1.0	13.2±0.5	31.8±0.1	64.±1.5	0.55
RH16	Mesothelioma	10.4±0.7	10.7±0.5	15.6±0.1	35.3±2.4	0.22
MKN28	Stomach	4.9±2	15.2±1.8	5.2±0.1	57.1±6.4	0.20
NUGC4	Stomach	7.7±1.2	14.6±1.2	8.8±0.2	53.9±0.5	0.17
KB 31	Cervical	5.0±0.5	9.2±0.8	6.2±2.1	56.8±0.7	0.10
L55	Lung	9.9±0.35	19.8±1.1	9.3±2.1	35.7±8.8	0.36

Numbers are percentage of dead cells subtracted from control with SEM. Tumor cells were preincubated with panbinostat (Panb) at 5 nM for 6 hours, then incubated with either 10 nM (RH16, NUGC4), or 20 nM (KLM1, HAY, MKN28, L55), or 30 nM (BxPC3, KB 31) of panbinostat, with or without LMB-100 at 5 ng/ml (HAY, NUGC4), or 10 ng/ml (KLM1, MKN28, RH16), or 50 ng/ml (L55), or 100 ng/ml (BxPC3 and KB31) for 3 days for all cells except RH16 and MKN28, which were treated for 4 days. Cell death was determined by FACS analysis after staining of annexin-V and 7-AAD. The data was generated from 2 or 3 separate experiments. CI was calculated by the Bliss independence model {CI=(Ea+Eb-EaEb)/Eab}.